NEWS

Metcela participated in “Research Studio 2018 powered by SPARK”, an acceleration program organized by Tsukuba Clinical Research & Development Organization (T-CReDO), and won the grand prize in the final pitch.

Read more…

ASCII HealthTech wrote an article about Metcela on 10th October, 2018 (Japanese)

http://ascii.jp/elem/000/001/748/1748926/

Metcela Inc., a biotech startup specializing in fibroblast-based cell therapy, announced today that the New Energy and Industrial Technology Development Organization (NEDO) has awarded the company with the Hashiwatashi grant (up to 100 million yen) to support research and development activities for VCAM-1-positive Cardiac Fibroblast (VCF-1), leading up to initiation of a clinical trial for heart failure patients in Japan.

Read more…

With this financing, Metcela has now raised a total of 920 Million yen including the previous investments and grants

Metcela, a biotech startup specializing in fibroblast-based cell therapy for heart failure treatment, announced the successful closing of its 520 million yen ($4.6 million) Series A round. The round was led by Beyond Next Ventures, with additional participation from new investors, Eight Road Ventures Japan, F-Prime Capital Partners, Japan Lifeline Co., Ltd., Sony Innovation Fund, The Dai-ichi Life Insurance Company, Limited, and KSP Inc. With this financing, Metcela has raised a total sum of 920 million yen ($8.2 million), including previously raised investments and grants.

Read more…

Nikkei Shinbun wrote an article on Metcela on 18th September 2017 (Japanese).

https://www.nikkei.com/article/DGKKZO21214120V10C17A9TJE000/